Immunogenicity of tumor-associated antigens (TAA) is often weak because many TAA are autoantigens for which the T-cell repertoire is sculpted by tolerance mechanisms. Substitutions at main anchor positions to increase the complementarity between the peptide and the MHC class I (MHC-I) binding cleft constitute a common procedure to improve binding capacity and immunogenicity of TAA. However, such alterations are tailored for each MHC-I allele and may recruit different CTL specificities through conformational changes in the targeted peptides. Comparative analysis of substituted melanomadifferentiation antigen gp100 in complex with H-2D b revealed that combined introduction of glycine and proline residues at the nonanchor positions 2 and 3, respectively, resulted in an agonistic altered peptide with dramatically enhanced binding affinity, stability, and immunogenicity of this TAA. Peptide vaccination using the p2Gp3P-altered peptide version of gp100 induced high frequencies of melanoma-specific CTL in the endogenous CD8 + repertoire. Crystal structure analysis of MHC/peptide complexes revealed that the conformation of the modified p2Gp3P-peptide was similar to the wild-type peptide, and indicated that this mimotope was stabilized through interactions between peptide residue p3P and the tyrosine residue Y159 that is conserved among most known MHC-I molecules throughout mammalian species. Our results may provide an alternative approach to enhance MHC stabilization capacity and immunogenicity of low-affinity peptides for induction of robust tumor-specific CTL. [Cancer Res 2009;69(19):7784-92] 
Introduction
The identification of a large number of tumor-associated antigens (TAA) that may serve as targets for CD8 + CTLs has stimulated research on the potential exploitation of MHC class I-binding peptide epitopes for immunotherapy of cancer (1, 2) . An important category of TAA comprises nonmutated tissue differentiation antigens that represent overexpression or aberrant expression of the proteins (3) . Due to immune tolerance, the avidity of anti-TAA T-cells is of moderate-to-low quality resulting in poor immunogenicity. Consequently, it is difficult to activate TAAspecific T cells upon using cognate low-affinity nonmodified tumor/self-peptide antigens. This represents a major challenge for the design of cancer vaccines.
Although clinical effectiveness has been disappointing until now (1) , the use of peptides as therapeutics has received renewed enthusiasm due to recent advances in design, delivery, and stability of vaccine formulations (4, 5) . The most common procedure to improve the effectiveness of vaccines comprising tumor/selfantigens is to increase the MHC binding affinity of TAA epitopes by substituting key peptide anchor positions with residues that display more appropriate properties (6) (7) (8) . However, such tailorbased improvements may alter the conformation of the presented peptide and/or do not always result in enhanced T-cell recognition of the native target sequence (9, 10) .
The melanocyte differentiation antigen gp100, an antigen naturally expressed by both normal melanocytes and the majority of malignant melanomas (11) , is an attractive TAA candidate for use in vaccines. Previous studies showed that in contrast to the corresponding natural mouse peptide gp100 [25] [26] [27] [28] [29] [30] [31] [32] [33] (EGSRNQDWL, hereafter called EGS), the human orthologue CTL epitope gp100 [25] [26] [27] [28] [29] [30] [31] [32] [33] (KVPRNQDWL, KVP) induced ''self ''-reactive CTL responses (12) . Although EGS and KVP differed only at the first three NH 2 -terminal nonanchoring positions (p1-p3) and that both peptides contain the motif required for binding to H-2D b , with an asparagine and a leucine residue at positions 5 (p5N) and 9 (p9L), respectively, KVP binds with a 100-fold higher affinity to H-2D b . To elucidate the basis underlying this apparent paradox, as well as the relative contribution of the NH 2 -terminal residues 1 to 3, functional and structural analyses of the two peptides and all permutated versions were performed.
In contrast to previous studies that aimed to optimize the complementarity between peptide anchoring residues and MHC pockets, our study shows that the combined introduction of a glycine and a proline at positions 2 (p2G) and 3 (p3P), respectively, enhanced binding affinity and stability of the modified peptides. The immunogenicity of the p2Gp3P-altered peptides was increased to a degree hitherto never observed, as measured through in vitro and in vivo assays. Vaccination with the modified peptide EGP (EGPRNQDWL) elicited high frequencies of EGS-specific CTL from the endogenous repertoire that efficiently targeted natural H-2D b / EGS complexes on melanoma tumor cells.
Comparison of the crystal structures of H-2D b in complex with EGS, KVP, and EGP revealed that the conformation of the three peptides is similar. The p2Gp3P modifications in EGP establish novel essential interactions within the binding cleft of H-2D b , mainly between p3P and heavy chain residue Y159, conserved among most known MHC-I sequences across species (13) . In conclusion, this study suggests an alternative approach for the design of optimal peptide mimotopes that overcome self-tolerance and could be used as target antigens for immunotherapy of cancer.
Materials and Methods
Reagents. All gp100 peptide variants were used as 9-mers, unless indicated otherwise. Purity and integrity of all peptides was assessed with reversed phase high performance liquid chromatography and mass spectrometry. CpG oligodeoxynucleotide 1826 was synthesized in the Leiden Institute of Chemistry. Imiquimod was obtained as Aldara (5% imiquimod; 3M Health Care Ltd). In our hands, imiquimod has proven to be a stronger adjuvant than CpG. Thus, CpG was used for transgenic pmel expansion data presented in Fig. 2 , whereas imiquimod was used for the expansion of endogenous T-cell populations in all other assays.
MHC binding affinity and stabilization assays. Mice. Male C57BL/6 mice were purchased from Iffa Credo. TCR transgenic mice containing gp100 25-33 /H-2D b -specific T-cell receptors (designated as pmel) were a gift from Dr. N.P. Restifo (National Cancer Institute, Bethesda, Maryland) and bred to express the congenic marker CD90.1. All mice were housed under specific pathogen-free conditions and used at 6 to 12 wk of age. Experiments were performed in accordance with Dutch national legislation and institutional guidelines.
Immunogenicity in TCR-transgenic pmel cells. Lymphocytes from spleen and lymph nodes of naïve CD90.1-positive pmel mice were isolated and enriched for T lymphocytes by nylon wool. Pmel cells were labeled with 5 Amol/L carboxyfluorescein diacetate succinimidyl ester (CFSE; Molecular Probes) and 3 Â 10 6 CD8 + T lymphocytes were adoptively transferred by injection into the tail vein. Mice were immunized 1 d later through s.c. injection of 50 Ag gp100 25-33 mixed in PBS with 25 Ag CpG. After 4 d, singlecell suspensions from spleen, draining, and nondraining lymph nodes were prepared for analysis. Lymphocytes were incubated for 3 h with 1 Ag/mL EGS and GolgiPlug (BD bioscience) and stained thereafter with fluorochromelabeled antibodies for intracellular IFN-g (XMG1.2) in combination with CD8a (53-6.7) and CD90.1 (HIS51; BD biosciences). Cells were analyzed using a FACS Calibur flow cytometer and Cell Quest Pro software (BD biosciences).
In vivo analysis of endogenous T-cell repertoire. For priming of endogenous T cells, C57BL/6 mice were shaved on the flank and injected s.c. at days 0 and 7 with PBS alone or 50 to 150 Ag 20-mer long peptides (EGSlong: AVGALEGS RNQDWLGVPRQL, KVP-long: AVGALKVP RNQD-WLGVPRQL, or EGP-long: AVGALEGPRNQDWLGVPRQL) in PBS. Immediately following injection, 60 mg of 5% imiquimod cream (Aldara) were applied to the skin at the injection site. Where indicated, mice received an additional i.p. injection of 600,000 IU human interleukin 2 (IL-2; Novartis) on the day of the second vaccination and one on the day thereafter. On day 10 to 15, splenocytes were harvested and stimulated in vitro with lipopolysaccharide-matured, irradiated (3,000 rad) dendritic cells (D1; ref. 16 ) loaded with 5 Ag/mL peptide. After 6 d, viable cells were isolated by ficoll density gradient and were either directly stained with a CD8-specific antibody and H-2D b /EGS tetramers (a gift from Dr. Schumacher, the Netherlands Cancer Institute, Amsterdam) or stained with antibodies specific for CD8 and intracellular IFN-g following overnight incubation with 5 Ag/mL EGS peptide. All analyses were performed using flow cytometry. Cytolytic activity of the peptide-stimulated splenocyte cultures was determined using tritium-thymidine-labeled B16 melanoma cells in a DNA fragmentation assay (17) . Peripheral blood lymphocytes samples were collected on day 13, and IFN-g production following overnight stimulation with EGS was determined. Plots are gated on live CD8 + lymphocytes.
In vivo cytotoxicity of endogenous gp100-specific CTL. C57BL/6 mice were vaccinated with 20-mer long peptides and imiquimod as described above. The mice were injected 8 d later i.v. with a mix of nonameric peptidepulsed CFSE-labeled splenocytes as described previously (18) . Briefly, spleens from CD90.1 congenic C57BL/6 mice were passed through nylon wool. Half of the splenocytes was pulsed with EGS and labeled with 0.5 Amol/L CFSE, whereas the other half was pulsed with control peptide E1A 234-243 and labeled with 5 Amol/L CFSE. Target cell populations were washed, mixed, and 50 Â 10 6 cells were injected per recipient mouse. Spleens of immunized mice were harvested after 2 d, stained with CD3-, CD8-, and CD90.1-specific antibodies, and analyzed with flow cytometry. Percentage killing was calculated as the ratio between the numbers of EGS-pulsed targets and control-pulsed targets.
Tumor protection experiments. C57BL/6 mice were inoculated with 20,000 B16F10 tumor cells s.c. in the flank. After 8 d, mice were adoptively transferred with 10 6 naïve pmel cells in the tail vein. Next day and 1 wk later, mice were shaved on the contralateral flank and injected s.c. with PBS alone or 150 Ag murine gp100 [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] long peptide containing either EGS, EGP, or KVP. Immediately following injection, 60 mg Aldara cream were applied to the skin at the injection site. Mice were also injected i.p. with 600,000 IU human IL-2 on the day of the second vaccination and on the day thereafter. + T cells. One representative experiment out of three is displayed (three mice per group). B, frequencies of EGS-specific CD8 + T cells were directly monitored from the blood of immunized C57BL/6 mice. Immunizations were performed with 20-mer long peptides comprising KVP, EGS, or EGP sequences and topical imiquimod as adjuvants (38 mice per group). *, P V 0.05; **, P < 0.001, and Student's t tests were performed using GraphPad software. C, left, spleens and lymph nodes harvested from peptide-immunized mice from B were stimulated once in vitro with the same peptide KVP (5), EGS (o), and EGP (.), and killing capacity was tested in a DNA fragmentation assay against B16 melanoma cells. C, right, in vivo killing assay in which C57BL/6 mice were injected with equal numbers of two differentially CFSE-labeled target cells. CFSE low-and high-labeled targets were exogenously pulsed with EGS and a control peptide, respectively. Percentage of killing was calculated by the ratio of the two targets in spleens of mice. Groups of four mice were analyzed. Columns, mean results; bars, SEM. *, P V 0.05; **, P < 0.001, and Student's t tests were performed using GraphPad software. D, B16 tumor cells were injected s.c. into naïve C57BL/6 mice. After 8 d, mice were vaccinated once with peptides KVP (5), EGS (o), and EGP (.) or naïve (Â) in combination with nonstimulated pmel cells. Mice were sacrificed when tumor sizes exceeded above 1 cm 3 . Kaplan-Meier survival curves of EGP-treated group (n = 9) and controls were significantly different (log-rank test in GraphPad); P = 0.0007. Arrow, the start of treatment (day 9). Comparable results were obtained in an additional independent experiment.
Tumor growth was measured in three dimensions twice weekly. Mice were sacrificed when tumors exceeded 1 cm 3 . Data collection and processing. Refolding and purification of H-2D b in complex with EGS, KVP, and EGP were conducted as previously described (19) . Crystals were obtained in hanging drops by vapor diffusion in 1.8M ammonium sulfate and 0.1M TrisCl (pH 9.0) at 4jC. Crystals were cryoprotected using 20% glycerol and diffraction data were processed using XDS (20) .
Structure determination and refinement. All structures were solved by molecular replacement using PHASER (21) with H-2D b /gp33 (19) as a search model. Model building was performed with COOT (22) combined with refinement using REFMAC (23) . TLS refinement was introduced in the last stages of refinement. Data collection and refinement statistics are summarized in Supplementary Table S1 .
Results and Discussion
Combined p2Gp3P substitution increases binding affinity and MHC-I stabilization capacity of altered peptides. To establish the relative contribution of peptide residues p1 to p3 to the observed higher binding affinity of KVP to H-2D b , six nonameric peptide variants corresponding to single amino acid permutations between EGS and KVP were generated. The binding affinity of peptides was determined through cell surface expression of H-2D b on TAP-deficient RMA-S cells (Fig. 1A) . Since it has been previously shown that stabilization of MHC-I by modified peptides enhances immunogenicity (24, 25) , the capacity of all peptides to stabilize cell surface expression of H-2D b was also assessed (Fig. 1B) .
Introduction of a lysine at position 1 of gp100 improves both its binding affinity and the stability of the complex as indicated upon comparing KGS and KVP with EGS and EVP, respectively (Fig. 1) . This is well in line with previous studies in which substitution of a lysine at position 1 altered the binding affinity of modified peptides to H-2D b (26) or H-2K b (27, 28) . Although the substitution of glycine to valine at position 2 (pG2V) did not modify the poor binding affinity and complex stability of EGS and EVS, the converse substitution (pV2G) improved both binding affinity and complex stabilization of KGP when compared with KVP (Fig. 1) . Thus, surprisingly, the removal of the side chain of the valine residue from the B-pocket upon mutating p2V to a glycine, in combination with a proline residue at position 3 of the peptide, was favorable for both binding affinity and stabilization capacity. Accordingly, substitution of serine in EGS to a proline also resulted in a striking improvement of binding affinity (of at least a 100-fold) and MHC stabilization capacity (Fig. 1) .
Taken together, our results show that the p2Gp3P combination dramatically improved the binding affinity and the MHC stabilization capacity of KGP and EGP. Mutation of a valine in KVP to a glycine in KGP increased both binding affinity and stabilization of H-2D b (Fig. 1) , implying that the effect of a proline residue at p3 was improved by the introduction of a glycine in the flanking residue p2. Similarly, introduction of a proline at position 3 in EGP dramatically improved both affinity and stability when compared with EGS (Fig. 1) . The interdependency of the two residues is shown upon direct comparison of peptides harboring p2Vp3P or p2Gp3P (Supplementary Fig. S1 ). Our results indicate that (a) the potential effects of a modification at a specific position of the altered peptide onto adjacent peptide residues should be carefully evaluated and (b) modification of the size of a residue to increase interactions with MHC pockets can be directly detrimental to the overall binding affinity of the altered peptides.
The p2Gp3P-substituted peptides are highly immunogenic in vivo. The peptides EGS, KVP, and the six altered analogues were tested using T-cell receptor transgenic pmel cells, specific for H-2D b in complex with EGS (29) . CFSE-labeled CD8 + pmel T-cells were adoptively transferred into CD90.2 congenic host mice that were subsequently vaccinated with the eight different peptide variants. The pmel T-cell responses were assessed in terms of expansion, number of divisions, and IFN-g production in draining lymph nodes (Supplementary Fig. S2; Fig. 2 ). Immunization with EGS resulted in limited proliferation and activation of pmel cells, whereas nonimmunized mice did not harbor any proliferated CTL. In contrast, immunization with EGP resulted in significant clonal expansion and IFN-g production of pmel T cells. As expected, immunization with KVP resulted in slightly higher proliferation when compared with EGS (Fig. 2) . However, IFN-g production and cell division were limited. Again, immunization with KGP resulted in dramatic increases of pmel activation (Supplementary Fig. S1B-D;  Fig. 2) . Importantly, similar results were also obtained in spleen and nondraining lymph nodes, indicating that the activated pmel cells harbored the capacity to spread systemically ( Supplementary  Fig. S3 ). In conclusion, the introduced p2Gp3P modifications in EGP and KGP result in strong in vivo immunogenicity combined with increased binding affinity and strong stabilization of H-2D b , generating a very potent peptide vaccine.
Vaccination with EGP induces robust CTL responses from the endogenous T-cell repertoire. Groups of C57BL/6 mice were vaccinated with each of EGS, KVP, and the p2Gp3P-altered peptides EGP and KGP in combination with the TLR7 ligand imiquimod as an adjuvant (30) . The reactivity of vaccine-induced CD8 + T cells isolated from spleens and lymph nodes was analyzed in vitro (Fig. 3A) . Vaccination and in vitro stimulation with EGS did not yield any detectable peptide-specific T-cells, whereas vaccination and stimulation with KVP led to significant numbers of KVP-reactive T cells that efficiently cross-reacted with EGS. Interestingly, KGP was strikingly immunogenic in C57BL/6 mice and up to 75% of all endogenous CD8 + T cells in ex vivo cultures were specific for this peptide. However, KGP-reactive T cells cross-reacted with EGS only at relatively high concentrations, indicating that KGP promoted the expansion of T cells with a different fine specificity. Finally, EGPinduced T-cell responses displayed the most favorable characteristics: they were present at high frequencies and cross-reacted to very low concentrations of the natural target EGS. Thus, in contrast to KGP, residue p1E in EGP most likely constrains the recruited T-cell pool to cells that cross-react with EGS. Due to the relatively lower cross-reactivity displayed by KGP-induced T cells toward the original peptide EGS, we hereafter focused our analyses on EGP.
Vaccination with EGP induces melanoma-reactive CTL. Peptide vaccination can be strongly improved through the use of longer peptides that comprise minimal CTL epitopes in combination with adequate adjuvants that activate the innate immune system (4, 18) . The immunotherapeutic potential of EGP was assessed against the aggressive B16 melanoma that expresses the gp100 antigen EGS. Ex vivo analyses of C57BL/6 mice immunized with EGS-long (AVGALEGSRNQDWLGVPRQL), KVP-long (AVGAL-KVPRNQDWLGVPRQL), or EGP-long (AVGALEGPRNQDWLGVP-RQL) combined with topical application of imiquimod resulted in very high frequencies of EGS-specific CD8 + T cells in the blood of EGP-injected animals, with numbers up to 50% of the total CD8 + cell population (Fig. 3B) , clearly overruling the potency of the other peptides. Further analysis with tetramers of H-2D b /EGS complexes corroborated these results (Supplementary Fig. S4 ). The CD8 + T cells raised by EGP efficiently killed B16 melanoma cells in vitro (Fig. 3C, left) as well as peptide-loaded targets in vivo (Fig. 3C,  right) . In all experiments, KVP performed better than EGS, but was far less efficient when compared with EGP. In all animals immunized with EGP, the induced CTL population displayed a broad repertoire of TCR variable regions comparable with other peptide variants ( Supplementary Fig. S5 ). The relatively higher frequency of Vh13
+ TCRs in all four tested peptides indicates that this segment optimally suites the MHC/peptide complex. Of note, Vh13 is also used by the transgenic pmel TCR. Finally, the immunotherapeutic potential of EGP was tested against established B16 mouse melanomas. C57BL/6 mice were inoculated with a tumorigenic dose of melanoma and treated from day 9, when subclinical tumors were established. Therapeutic vaccination with EGP-long led to significant numbers of CTLs in blood and within tumor beds, resulting in a delay of tumor outgrowth by 11 days (data not shown). Addition of naïve pmel cells at day 8 in the treatment scheme was sufficient to eradicate established melanomas in half of the EGP-treated group (Fig. 3D) . Interestingly, no overt sign of autoimmune pathology or ocular autoimmunity (31) was observed in the surviving mice during the time frame of the experiments (4 months). In conclusion, the introduction of a proline residue at position 3 in the very weak tumor CTL epitope EGS transformed it into the strongly agonistic peptide EGP that can be used as a powerful vaccine capable of inducing effective antitumor CTL responses.
Structural basis underlying improved binding stability and immunogenicity in p2Gp3P-altered peptides. The overall conformation of the peptide-binding clefts is conserved in the crystal structures of H-2D b in complex with EGS, KVP, and EGP, with overall root mean square deviations inferior to 1.1Å for C a atoms of residues 1-176. Importantly, the conformation of all residues that potentially interact with the TCR and the two main anchor positions p5N and p9L is conserved among all three MHC complexes (Supplementary Fig. S6; Fig. 4A ) and can thus not explain the differences in binding affinity and stabilization. Furthermore, similar amounts of hydrogen bond interactions are formed between H-2D b and the three peptides. However, comparative structural analysis indicated subtle but important differences at positions 2 and 3 as a structural basis for the higher affinity and stability of EGP when compared with KVP and EGS. A hydrogen bond interaction is formed in all three structures between the hydroxyl group of Y159, conserved among most known MHC-I molecules (13) , and the oxygen atom of peptide residue p1, resulting in a precise orientation of the side chain of Y159 (Fig. 4B) . Proteins can use the hydroxyl of tyrosines to position their ring precisely (32) . Furthermore, the involvement of the hydroxyl group of a tyrosine as a hydrogen bond donor enhances the electronegativity of the tyrosine ring and promotes the formation of CH-k interactions with adjacent residues, such as in this case p3P in the bound peptide (32, 33) .
Although few interactions are formed between H-2D b and residues p2G and p3S in H-2D b /EGS (Fig. 4B) , the side chain of p2V in H-2D b /KVP makes van der Waals contacts with residues Y7 and Y45 in the B-pocket. Importantly, the pyrrolidine ring of p3P fits better within the C pocket, when compared with p3S in H-2D b / EGS, mostly through extensive interactions with residue Y159. CH-k interactions are formed between p3P and Y159. Engagement of the pyrrolidine ring of a proline with an aromatic ring, especially when it leads to CH-k interactions, provides substantial binding energy (32) (33) (34) (35) (36) . Indeed, CH-k interactions play an important role for molecular recognition in biological receptors and contribute significantly to the overall stability of proteins (34, 37) .
Our functional studies pointed at the strong interdependence between p2G and p3P in the p2Gp3P-altered peptides. The bulky pyrrolidine ring of the proline restricts the conformational freedom of the preceding residue (38) , and although p2V is not unfavorable to binding of KVP, the positioning of the side chain of p2V will be constrained by sterical hindrances within the in the acidic B-pocket. The parallel positioning of the side chains of prolines and tyrosines is important for optimal formation of CH-k interactions (32) (33) (34) . Thus, as a consequence of the positioning of p2V within the B-pocket, CH-k interactions between p3P and Y159 are not optimal in H-2D b /KVP. In contrast, the p2Gp3P combination in H-2D b /EGP allows for a translational movement of this section of the peptide (Fig. 4C ) with at least three consequences. First, the side chain of p3P is shifted by 0.8Å in H-2D b /EGP when compared with H-2D b /KVP, resulting in an optimal positioning of p3P and Y159 (Fig. 4D) . As a consequence, van der Waals, CH-k, and electrostatic interactions are enhanced. Second, the side chain of p3P binds deeper within the peptide binding cleft (0.8Å shift when compared with p3P in H-2D b /KVP), increasing the van der Waals interactions with H-2D b residues E9, Q97, S99, and Y159. Third, CH-O interactions are formed between the C y -H group of p3P and residues E9 and S99 (0.8Å shift when compared with p3P in H-2D b / KVP). In conclusion, the p2Gp3P combination allows for optimal CH-k and van der Waals interactions between p3P and heavy chain residue Y159, conserved among most known MHC-I molecules (13 (40) , and MCF env 143-150 (15) led to significant increase of binding affinity (Fig. 5) , suggesting that our approach may be applicable to a broad range of weakly binding peptides restricted to H-2D b and H-2K b . Although the introduction of p2Gp3P substitutions in the peptide carcinoembryonic antigen (CEA; ref. 41) with intermediary affinity to H-2D b increased binding affinity marginally, this result was obtained in three separate experiments. Due to the conservation of the heavy chain residue Y159 among most known MHC class I alleles, one may speculate that similar results could be obtained with weakly binding peptides restricted to other mouse and human MHC alleles.
Concluding remarks. This study shows that the p2Gp3P-altered peptide EGP mimics the wild-type melanoma-associated EGS, enhancing the stabilization of MHC complexes and immunogenicity (42) . Structural conservation relieves concerns on unwanted side effects, such as the generation of CTL populations that do not properly cross-react with the natural ligand, as recently reported for MART-1/MelanA (10).
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